Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
申请人:Cayman Chemical Company, Inc.
公开号:US11066361B2
公开(公告)日:2021-07-20
Disclosed herein are compounds of formula (I)
and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
此处公开的是式 (I) 化合物
以及用式(I)化合物进行治疗的方法,其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式(I)化合物是 EP4 激动剂,可用于治疗青光眼、神经性疼痛及相关疾病。